Use of Dapagliflozin to Reduce Burden of Atrial Fibrillation in Patients Undergoing Catheter Ablation of Symptomatic Atrial Fibrillation (DAPA-AF) Prospective, Randomized, Multicenter, Placebo-Controlled Trial
Latest Information Update: 06 Dec 2024
At a glance
- Drugs Dapagliflozin (Primary)
- Indications Atrial fibrillation
- Focus Therapeutic Use
- Acronyms DAPA-AF
Most Recent Events
- 09 Aug 2023 Status changed from active, no longer recruiting to completed.
- 07 Oct 2022 Time frame changed from 12 months to 6-12 months.
- 07 Oct 2022 Planned End Date changed from 1 Jun 2024 to 30 Jun 2023.